A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis

Summary

The purpose of this study is to evaluate if study drug mirikizumab is safe and effective compared to vedolizumab and placebo in participants with moderately to severely active ulcerative colitis (UC).

Timeline

Start

2021-04-20

Primary completion

2024-03-13

Completion

2024-06-05

Outcome

Outcome not reported

Stopped (Business): “The trial was terminated secondary to a business decision, the original scientific question rendered moot by the external scientific community.”

Drugs

Indications